Detailed Narrative
Socalitinib Development Focus
Corvus Pharmaceuticals is primarily focused on advancing socalitinib, their first-in-class selective ITK inhibitor, across multiple indications. Key efforts are directed towards driving patient enrollment and executing clinical trials for its two lead opportunities: the Phase 3 peripheral T cell lymphoma (PTCL) program and the Phase 2 atopic dermatitis program. The company also plans to initiate trials in hidradenitis suppurativa (HS) and asthma, leveraging the broad potential of ITK inhibition to reset immunity.
PTCL Phase 3 Progress
The Phase 3 trial in relapsed/refractory PTCL is enrolling 150 patients randomized 1:1 to socalitinib or standard of care chemotherapy. Enrollment is on track, with an interim futility analysis by an independent data monitoring committee expected in Q1 2027. The primary endpoint is progression-free survival (PFS), which currently has a median of about three months with existing treatments. No safety or efficacy data will be publicly released at the time of the futility analysis.
Atopic Dermatitis Phase 1 Data and Phase 2 Trial
Final data from the randomized, blinded, placebo-controlled Phase 1 trial in moderate to severe atopic dermatitis showed positive efficacy and safety. In cohort four, 75% of socalitinib patients achieved EZ75 compared to 20% of placebo, with 25% achieving EZ90 and 33% achieving IGA0 or 1. Efficacy was observed in treatment-resistant patients, showing a dose-dependent trend and prolonged benefit beyond dosing, correlating with Treg induction. The Phase 2 Sierra trial is currently enrolling approximately 200 patients, with enrollment completion anticipated in early 2027 and top-line data in Q3 2027.
Angel Pharma Collaboration in China
Corvus is collaborating with Angel Pharmaceuticals on a Phase 1B2 clinical trial of socalitinib in moderate to severe atopic dermatitis in China. This trial has a similar design to Corvus's Phase 2, evaluating 12-week treatment regimens. Enrollment for Cohort 1 is expected to complete in September 2026, with data available before year-end 2026. Data from Cohort 2 is anticipated in Q2 2027. The Angel data, combined with Corvus's own, could position the company to start a global Phase 3 trial by the end of 2027.
Expansion into HS and Asthma
Corvus plans to initiate a Phase 1B proof-of-concept trial in hidradenitis suppurativa (HS) in September 2026, enrolling up to 25 patients with moderate to severe disease, focusing on safety and TH17 biomarker effects. Concurrently, a Phase 2 asthma trial will begin later this year, designed to enroll both allergic (T2) and non-allergic (non-T2) asthma patients, addressing a broader population than most current treatments. Angel Pharmaceuticals also expects to start a Phase 2 asthma trial in early 2027.
Financial Overview
For Q2 2026, R&D expenses increased to $16 million from $7.9 million in Q2 2025, driven by higher clinical trial costs for socalitinib. The net loss for the quarter was $18 million, up from $8 million in Q2 2025. As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $215.2 million, including $189.4 million in net proceeds from a Q1 follow-on offering. This cash position is expected to fund operations into Q2 2028.